TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2025 and provided its financial guidance for the year ending June 30, 2026. Highlights for the three months ended June 30, 2025 (compared to the three months ended June 30, 2024) Net sales of $378.7 million, an increase of $105.5 million, or 39% Net income of $17.2 million, an increase of $16.5 million
Related Questions
How will the 39% sales growth and doubled net income affect PAHC's valuation multiples and price target?
What are the key drivers behind the earnings beat, and are they sustainable in the upcoming fiscal year guidance?
How does PAHC's performance and guidance compare to peer companies in the animal health sector, and what impact might this have on relative positioning in the market?